Participated · Series B · Jul 2021

Leo Cancer Care develops an integrated upright platform that applies the same seating-based architecture across imaging, photon therapy and proton therapy. Its upright imaging system is FDA-cleared and is used for treatment planning and has planned future radiology applications. On the treatment side, its Marie® platform enables a compact upright proton therapy room by fixing the beam and rotating a seated patient, a design that Stanford Medicine used to deliver the world’s first compact upright proton treatment on June 4, 2026. The company reports adoption by leading centers including Stanford Medicine, Dana-Farber Cancer Institute and McLaren Health Care and says its approach can enable installations in existing radiotherapy vaults. Leo plans to use the $65M Series D to scale manufacturing, accelerate commercial deployment globally, and continue clinical and product development across its proton, photon and imaging offerings.